These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24808675)

  • 21. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
    Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA; Vinluan CM; Antony N
    Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?
    Sanders CC; Moland ES
    Clin Drug Investig; 1995 Dec; 10(6):344-54. PubMed ID: 27519336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.
    Sader HS; Castanheira M; Flamm RK; Huband MD; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):473-8. PubMed ID: 27104633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of the genes encoding extended-spectrum beta-lactamases, in Escherichia coli resistant to beta-lactam and non-beta-lactam antibiotics.
    Matar GM; Al Khodor S; El-Zaatari M; Uwaydah M
    Ann Trop Med Parasitol; 2005 Jun; 99(4):413-7. PubMed ID: 15949189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa.
    Neu HC; Chin NX; Novelli A
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1666-75. PubMed ID: 3150915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of different phenotypic methods detecting extended spectrum beta-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii strains].
    Zarakolu P; Metan G; Hasçelik G; Akova M
    Mikrobiyol Bul; 2005 Jul; 39(3):265-72. PubMed ID: 16358485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
    Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
    Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftazidime for respiratory infections.
    Choi SH; Koh Y
    Expert Opin Pharmacother; 2012 Oct; 13(14):2097-109. PubMed ID: 22943280
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative in vitro study of the antimicrobial activity of ceftazidime against clinical isolates].
    Klietmann W; Focht J; Nösner K
    Infection; 1987; 15 Suppl 4():S145-9. PubMed ID: 3312026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of ceftazidime and newer antibiotics against Gram-negative bacilli.
    Schassan HH; Fedder J
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():79-82. PubMed ID: 19802973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.